FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Sanofi asks for Zentiva extension, again

Tools

Like an army besieging the castle keep, Sanofi-Aventis stands waiting...waiting...hoping to crack its quarry's defenses. The drugmaker has asked yet again to extend its offer for Czech generics firm Zentiva. The current offer expires Friday.

But barring a sweetened offer, it's tough to see just how Sanofi might prevail. Earlier this month, Zentiva repeated its contempt for the 1,050 crown-a-share bid, saying it undervalues the company. And as BNet notes, Sanofi seems to need Zentiva more than Zentiva needs Sanofi. The bigger company has its share of the troubles plaguing pharma, while Zentiva is on a growth curve.

- get the news from EasyBourse
- read the BNet item

Related Articles:
Zentiva spurns Sanofi's buyout offer
Zentiva calls meeting on Sanofi bid
Sanofi launches $1.92B Zentiva offer
PPF leaves Zentiva to Sanofi


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FiercePharma Email Newsletter:

More stories about Generics   Sanofi-Aventis   Mergers and Acquisitions   Zentiva